Literature DB >> 26942094

Doubling the blockade for melanoma immunotherapy.

Lorenzo Galluzzi1, Alexander Eggermont2, Guido Kroemer3.   

Abstract

Entities:  

Keywords:  CTLA4; PD-1; ipilimumab; metastatic melanoma; nivolumab; pembrolizumab

Year:  2015        PMID： 26942094      PMCID： PMC4760293          DOI： 10.1080/2162402X.2015.1106127

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  51 in total

Review 1.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 2.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab.

Authors:  Rikke Andersen; Peter Nørgaard; Mohamad Kadhem Mohamad Al-Jailawi; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2014-08-03       Impact factor: 8.110

5.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer.

Authors:  Aizea Morales-Kastresana; Sara Labiano; Ines Gütgemann; Ignacio Melero
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110

Review 9.  Trial Watch: DNA vaccines for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-04-01       Impact factor: 8.110

Review 10.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-05-01       Impact factor: 8.110
View more
  7 in total

1.  Novel immune checkpoint blocker to treat Merkel cell carcinoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

Review 2.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

Review 3.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 4.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 5.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 6.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 7.  Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.

Authors:  Georg Richtig; Barbara Ehall; Erika Richtig; Ariane Aigelsreiter; Tony Gutschner; Martin Pichler
Journal:  Int J Mol Sci       Date:  2017-03-28       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.